Boomi CEO Steve Lucas Releases New Book: Digital Impact — The Human Element of AI-Driven Transformation
Boomi, the intelligent integration and automation leader, today announced the release of Digital Impact: The Human Element of AI-Driven Transformation (Wiley), a bold new book by Boomi Chairman and CEO Steve Lucas. In it, Lucas makes a powerful case for a problem few business leaders are talking about: the AI revolution is doomed to stall unless we first fix the broken digital infrastructure that supports it.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250415679642/en/
Boomi CEO Steve Lucas Releases New Book: Digital Impact — The Human Element of AI-Driven Transformation
With nearly 30 years of leadership at companies including Adobe, SAP, Salesforce, and Marketo, Lucas shares a firsthand playbook for addressing the crisis of digital fragmentation — outdated systems, disconnected data, and chaotic architectures — that threatens to derail enterprise AI.
“AI is only as smart as the systems and data it runs on,” said Lucas. “Right now, most companies are trying to build AI skyscrapers on sand. But with the right integration strategy — one that puts people first — we can turn digital chaos into a catalyst for innovation, sustainability, and human progress.”
Featuring exclusive interviews with enterprise leaders and a foreword on the coming AI era, Digital Impact provides a roadmap for creating connected, intelligent, and human-centered digital environments. The book introduces Lucas’s “Digital Impact Mission,” a new leadership framework that calls on CEOs to lead transformation from the top, fix fragmentation first, and prioritize technology that empowers people.
Praise for Digital Impact from business luminaries includes:
“Every industry, every company, every workflow is being reinvented with AI. Organizations face the monumental task of embracing the opportunity in this transformative moment. Digital Impact provides a blueprint for navigating the AI revolution.”
— Bill McDermott, CEO, ServiceNow
“Embracing AI is now an imperative for businesses seeking a step-function change in productivity. Digital Impact compels you to reject fear of the unknown and turn AI into one of your most transformational business assets.”
— Carl Eschenbach, CEO, Workday
“People don’t yet understand how important integrating systems and data will be to succeeding in the age of AI. Digital Impact will help you leave your competitors in the dust.”
— Betsy Atkins, former Chairman and CEO, Clear Standards, Inc.
“Business, like sports, needs an innovative game plan to keep you ahead of the competition. Digital Impact provides real-world examples and practical advice for how you can win your game.”
— Jonathan Becher, President, San Jose Sharks Sports & Entertainment
Digital Impact also explores compelling case studies, from banks modernizing legacy data systems to global logistics companies building real-time supply chain intelligence and not-for-profits using connected tech to drive change.
Available today, Digital Impact: The Human Element of AI-Driven Transformation is a must-read for any leader looking to unlock the full power of AI by building a smarter, more connected digital foundation — one designed with people and purpose at the center.
To learn more, visit:www.boomi.com/digitalimpact
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With over 23,000 customers globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415679642/en/
Contacts
Media:
Kristen Walker | (415) 613-8320 | kristenwalker@boomi.com
David Wolpert | (972) 743-8477 | david@fortierpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom